Vivani advances development of semaglutide implant

Vivani is ramping up its work on a semaglutide implant, pushing the boundaries of what’s possible with GLP-1 research compounds. While most researchers are used to semaglutide as an injectable, Vivani’s approach is all about long-acting delivery. This could mean less hassle in studies where consistent peptide presence is critical.

The implant technology aims to provide steady, controlled levels of semaglutide over extended periods. That’s a big deal for researchers who want to bypass the peaks and valleys you get from intermittent dosing. Instead of juggling injections or managing compliance, an implant could keep things nice and stable—just set it and let the research run.

Key points from Vivani’s development:

For peptide researchers, this is a potential game-changer. Imagine designing studies around consistent baseline peptide levels, without the logistical headaches. It also opens the door to new types of research questions: How does chronic, steady-state GLP-1 activity compare to intermittent spikes? What’s possible when you remove the variable of daily administration?

Vivani’s push on the semaglutide implant is a reminder: delivery tech matters as much as the peptide itself. The research community will be watching closely to see how this platform evolves and what it unlocks next.